IDH2
7 abstracts
Abstract
Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis.Org: Timone University Hospital Centre, University of Medicine 'I. Hatieganu' Cluj Napoca, University Hospital Timone, Marseille, France,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).Org: Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitario 12 de Octubre, Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Institute of Oncology (VHIO), Institut Catala d'Oncologia Badalona,
Abstract
Methylation-based prediction of myelodysplastic syndrome survival outcomes.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Columbia University - Mailman School of Public Health, Columbia University Medical Center,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Incidence of non-canonical IDH mutations and IDH co-mutations in a multicenter prospective study of patients with glioma.Org: Hospital Clinico Universitario San Carlos (IdISSC), Hospital Universitario San Carlos, Hospital Clinico Universitario San Carlos Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Universitario La PaZ (IdiPAZ), Hospital Clínico San Carlos,
Abstract
The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical Universityand Shandong Academy of Medical Sciences, Sino-US Diagnostics Lab,